Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

Jul 08, 2020
|
Molika Ashford

NEW YORK – The past few years have seen a significant shift in payor attitudes toward liquid biopsy cancer testing, including recent growth in the number of positive coverage policies and a shift toward pan-cancer versus cancer-specific implementation, a new study published this Monday has found.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Cancer

  1. Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

    Premium

  2. Guardant Health Enters CDx Collaboration With Radius Health for Elacestrant in HER2- Breast Cancer

  3. Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

  4. Exact Sciences Q2 Revenues Up 35 Percent, Buoyed by COVID-19 Testing Sales

  5. Sema4 Raises $121M in Series C Financing Round

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.